Modern cancer therapy has successfully cured many cancers and converted a terminal
illness into a chronic disease. Because cancer patients often have coexisting heart …

ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …

Background: Ibrutinib is a Bruton tyrosine kinase inhibitor with remarkable efficacy against B-
cell cancers. Ibrutinib also increases the risk of atrial fibrillation (AF), which remains poorly …

ABSTRACT Introduction The development of Bruton< apos;> s Tyrosine Kinase (BTK)
inhibitors has transformed the treatment of B-cell malignancies and other non-malignant …

Atrial fibrillation (AF) has been reported in up to 16% of patients taking ibrutinib. Data
regarding the management of AF in this patient population are limited, and stroke prevention …

Ibrutinib (IB) is an oral Bruton's tyrosine kinase (BTK) inhibitor that has demonstrated benefit
in B cell cancers, but is associated with a dramatic increase in atrial fibrillation (AF). We …

Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor finding increasingly widespread use in
non-Hodgkin lymphoma. Evidence of an increased risk of atrial fibrillation (AF) emerged in …

Atrial fibrillation, anticoagulant stroke prophylaxis and bleeding risk with ibrutinib therapy for
chronic lymphocytic leukaemia and lymphoproliferative disorders. - Abstract - Europe PMC …

Btk is an attractive target for the treatment of a range of Bcell malignancies as well as several
autoimmune diseases such as murine lupus and rheumatoid arthritis. Several covalent …

Background. Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor approved for second‐line
treatment for mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and …